BML Capital Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed April 24, 2024), BML Capital Management, LLC reported 30 stock positions worth $149.4 million. Its top holding was iShares 0-3 Month Treasury B (SGOV) at 18.2% of the portfolio, followed by Atea Pharmaceuticals (AVIR, 15.0%) and SS SPDR BB 1-3M T-Bill ETF (BIL, 12.3%). Compared with Q4 2023, it opened 6 new positions, sold out of 7, added to 10 and reduced 4. The biggest buy was a new position in Adverum Biotechnologies (ADVM) and the biggest sale an exit from Tourmaline Bio (TRML).
- Most Recent 13F
- Q2 2026
- Location
- ZIONSVILLE, IN
- CIK
- 0001616824
- Portfolio Value
- $149.4M (Q1 2024)
- SEC Filing
- 0001754960-24-000178 ↗ filed Apr 24, 2024
Holdings Value
Holdings 30 stocks · $149.4M
| SGOV iShares 0-3 Month Treasury B | 18.21% | 270,000 | $27.2M | No change |
| AVIR Atea Pharmaceuticals Inc. | 14.98% | 5,536,710 | $22.4M | Add +1.4% |
| BIL SS SPDR BB 1-3M T-Bill ETF | 12.29% | 200,000 | $18.4M | No change |
| ADVM Adverum Biotechnologies Inc. | 7.89% | 833,117 | $11.8M | New |
| ACRS Aclaris Therapeutics Inc. | 7.80% | 9,395,934 | $11.7M | Add +1338.7% |
| CYTT Cyteir Therapeutics Inc. | 7.36% | 3,654,053 | $11.0M | Add +12.4% |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 4.02% | 2,193,742 | $6.0M | Add +0.6% |
| AVROBIO INC | 3.43% | 4,001,627 | $5.1M | No change |
| TIL Instil Bio Inc. | 2.52% | 348,735 | $3.8M | New |
| RENEO PHARMACEUTICALS INC | 2.42% | 2,177,913 | $3.6M | Add +65.7% |
| CNTB Connect Biopharma Hldgs Ltd. | 2.40% | 2,061,338 | $3.6M | Reduce 0.0% |
| DSGN Design Therapeutics Inc. | 2.37% | 879,478 | $3.5M | Reduce -14.6% |
| ATHIRA PHARMA INC | 1.65% | 900,000 | $2.5M | Reduce -38.1% |
| ORMP Oramed Pharmaceuticals Inc. | 1.65% | 844,496 | $2.5M | Reduce -33.1% |
| PMVP PMV Pharmaceuticals Inc. | 1.49% | 1,306,490 | $2.2M | New |
| ASTC Astrotech Corp. | 1.32% | 220,410 | $2.0M | No change |
| LENZ Lenz Therapeutics Inc. | 0.96% | 63,916 | $1.4M | New |
| KNTE Kinnate Biopharma Inc. | 0.89% | 498,851 | $1.3M | Add +6.5% |
| ARCA BIOPHARMA INC | 0.83% | 706,930 | $1.2M | No change |
| FORTE BIOSCIENCES INC | 0.82% | 1,761,702 | $1.2M | No change |
| MIST Milestone Pharmaceuticals Inc. | 0.73% | 606,145 | $1.1M | Add +37.0% |
| VRCA Verrica Pharmaceuticals Inc. | 0.71% | 180,000 | $1.1M | No change |
| LSTA Lisata Therapeutics Inc. | 0.59% | 284,669 | $888K | Add +5.5% |
| ELVN Enliven Therapeutics Inc. | 0.59% | 50,100 | $881K | Add +0.2% |
| VTGN Vistagen Therapeutics Inc. | 0.53% | 150,000 | $792K | No change |
| NXTC Nextcure Inc. | 0.46% | 306,465 | $683K | No change |
| CALC Calcimedica Inc. | 0.45% | 160,424 | $667K | Add +10.3% |
| QTTB Q32 Bio Inc. | 0.28% | 24,894 | $424K | New |
| TLIS Talis Biomedical Corp. | 0.25% | 42,743 | $374K | No change |
| ALLOVIR INC | 0.10% | 200,464 | $151K | New |
Options reported separately and not counted above: WING puts ($1.8M), ANF puts ($470K).
Portfolio Sells Q4 2023 → Q1 2024
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −5.07 |
| THRX Theseus Pharmaceuticals Inc. | Sold out | 0.00% | −3.54 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −2.71 |
| RAIN ONCOLOGY INC | Sold out | 0.00% | −1.28 |
| ATHIRA PHARMA INC | Reduce -38.1% | 1.65% | −1.14 |
| GRPH Graphite Bio Inc. | Sold out | 0.00% | −0.93 |
| ORMP Oramed Pharmaceuticals Inc. | Reduce -33.1% | 1.65% | −0.65 |
| NGNE Neurogene Inc. | Sold out | 0.00% | −0.38 |
| HOMOLOGY MEDICINES INC | Sold out | 0.00% | −0.36 |
| DSGN Design Therapeutics Inc. | Reduce -14.6% | 2.37% | +0.22 |
| CNTB Connect Biopharma Hldgs Ltd. | Reduce 0.0% | 2.40% | +0.48 |
Portfolio Buys Q4 2023 → Q1 2024
| ADVM Adverum Biotechnologies Inc. | New | 7.89% | +7.89 |
| ACRS Aclaris Therapeutics Inc. | Add +1338.7% | 7.80% | +7.26 |
| TIL Instil Bio Inc. | New | 2.52% | +2.52 |
| AVIR Atea Pharmaceuticals Inc. | Add +1.4% | 14.98% | +1.82 |
| PMVP PMV Pharmaceuticals Inc. | New | 1.49% | +1.49 |
| LENZ Lenz Therapeutics Inc. | New | 0.96% | +0.96 |
| RENEO PHARMACEUTICALS INC | Add +65.7% | 2.42% | +0.76 |
| QTTB Q32 Bio Inc. | New | 0.28% | +0.28 |
| MIST Milestone Pharmaceuticals Inc. | Add +37.0% | 0.73% | +0.14 |
| CALC Calcimedica Inc. | Add +10.3% | 0.45% | +0.12 |
| ALLOVIR INC | New | 0.10% | +0.10 |
| ELVN Enliven Therapeutics Inc. | Add +0.2% | 0.59% | +0.04 |
| LSTA Lisata Therapeutics Inc. | Add +5.5% | 0.59% | +0.01 |
| KNTE Kinnate Biopharma Inc. | Add +6.5% | 0.89% | +0.01 |
| CYTT Cyteir Therapeutics Inc. | Add +12.4% | 7.36% | −0.44 |
| CLYM Climb Bio Inc. | Add +0.6% | 4.02% | −0.62 |
Options Activity Q4 2023 → Q1 2024
| WING Wingstop Inc. | put | Reduce -11.1% | 800 | $1.8M |
| QQQ Invesco QQQ Trust Series 1 | put | Sold out | 300 | $661Kbefore exit |
| ANF Abercrombie & Fitch Co. Class A | put | Reduce -88.9% | 100 | $470K |
| BBW Build-A-Bear Workshop Inc. | put | Sold out | 1,500 | $465Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $175.1M | ACRS, AVIR, ENGN, KHC, OM |
| Q1 2026 | 15 | $155.4M | ACRS, AVIR, ORMP, TLYS, OM |
| Q4 2025 | 13 | $113.0M | ACRS, AVIR, ORMP, TIL, PMVP |
| Q3 2025 | 19 | $108.7M | ACRS, AVIR, ADVM, TIL, ORMP |
| Q2 2025 | 23 | $130.5M | AVIR, THRD, ACRS, TIL, EPIX |
| Q1 2025 | 27 | $123.6M | AVIR, ACRS, THRD, ADVM, ANTX |
| Q4 2024 | 25 | $161.0M | ACRS, SGOV, AVIR, ADVM, ANTX |
| Q3 2024 | 29 | $169.9M | SGOV, TIL, AVIR, ACRS, BIL |
| Q2 2024 | 27 | $136.5M | SGOV, AVIR, BIL, ACRS, ADVM |
| Q1 2024Amended | 30 | $149.4M | SGOV, AVIR, BIL, ADVM, ACRS |